Why Cycling Matters
Cycling — alternating between periods of peptide use (on-cycle) and periods without (off-cycle) — is one of the most misunderstood aspects of peptide protocols. Some peptides require cycling to maintain effectiveness. Some require cycling for metabolic safety. Some don’t need cycling at all. And some people cycle everything regardless, following patterns borrowed from anabolic steroid culture that don’t apply to peptides.
This guide provides evidence-based cycling recommendations for every peptide category, explains the actual mechanisms behind cycling needs, and gives you specific on/off schedules to follow.
The Two Reasons to Cycle
There are exactly two scientifically grounded reasons to cycle a peptide. Every cycling recommendation on this page traces back to one or both of these mechanisms.
1. Receptor Desensitization
When a receptor is continuously stimulated by an agonist, cells can reduce the number of receptors on their surface (downregulation) or reduce each receptor’s sensitivity to the signal (desensitization). The result is diminishing returns — you need more of the compound to achieve the same effect, and eventually even high doses stop working.
Not all receptors desensitize at the same rate. Some are remarkably resistant (the ghrelin receptor activated by MK-677 shows no desensitization after 2 years). Others desensitize rapidly (GHS-R1a desensitizes within 2-4 weeks of continuous Hexarelin exposure).
Cycling solution: Time off allows receptor populations to recover. Upregulated degradation pathways slow down. Receptor density returns to baseline. When you restart the compound, it works at full potency again.
2. Metabolic Safety
Some compounds produce progressive metabolic changes that become problematic with continuous long-term use — even if the receptor doesn’t desensitize. The primary examples are:
- MK-677: Progressive insulin resistance and fasting glucose elevation
- GHRP-6: Chronic cortisol elevation
- GH secretagogues generally: Sustained supraphysiological IGF-1 levels
Cycling solution: Time off allows metabolic markers to normalize. Insulin sensitivity recovers. Cortisol returns to baseline. IGF-1 drops back to endogenous levels.
What Is NOT a Reason to Cycle
- “To keep the body guessing” — this is a gym myth with no pharmacological basis
- “To prevent tolerance” — tolerance and desensitization are different things. True pharmacological tolerance (needing more for the same effect) only applies to compounds that desensitize
- “Because steroids need PCT” — peptides do not suppress the hypothalamic-pituitary axis the way anabolic steroids suppress the hypothalamic-pituitary-gonadal (HPG) axis. No PCT is needed for any peptide
Category-by-Category Cycling Protocols
GH Peptides (GHRH + GHRP Combinations)
Compounds: CJC-1295, Ipamorelin, GHRP-2, GHRP-6, Sermorelin, Tesamorelin
| Protocol | On-Cycle | Off-Cycle | Rationale |
|---|---|---|---|
| Standard | 8-12 weeks | 4 weeks | Prevents GHRP receptor adaptation; allows IGF-1 normalization |
| Conservative | 8 weeks | 4-6 weeks | Safer for metabolic markers; preferred for users over 50 |
| Extended (Ipamorelin + CJC only) | 12-16 weeks | 4-6 weeks | Ipamorelin’s selectivity allows longer cycles without meaningful desensitization |
| Clinical (prescribed) | Continuous with monitoring | Periodic breaks per provider | Some anti-aging clinics prescribe continuous CJC+Ipa with quarterly bloodwork |
Why CJC-1295 + Ipamorelin can run longer than other combos: Ipamorelin is the most selective GHRP — it does not elevate cortisol, prolactin, or cause significant appetite changes. Its desensitization rate is the slowest of any GHRP. CJC-1295 (no DAC) also shows minimal receptor desensitization at standard doses. This combination can often run 12-16 weeks before any decrease in GH pulse amplitude is noticed.
Why GHRP-6 cycles should be shorter: GHRP-6’s cortisol elevation becomes a compounding problem over time. By week 8, chronic cortisol elevation can impair sleep, promote abdominal fat storage, and reduce immune function. Limiting GHRP-6 cycles to 4-8 weeks prevents cortisol-related side effects from accumulating.
Hexarelin is a special case: Hexarelin desensitizes the GHS-R1a receptor within 2-4 weeks of continuous use. It is essentially unusable for standard cycling protocols. If used at all, it should be limited to 2-week bursts followed by 4-6 weeks off. Most users are better served by Ipamorelin or GHRP-2.
MK-677 (Ibutamoren)
MK-677 breaks the standard cycling rules because it does not cause receptor desensitization — the GH-releasing effect remains consistent even after 2 years of continuous use (Nass et al., 2008). The reason to cycle MK-677 is entirely metabolic.
| Protocol | On-Cycle | Off-Cycle | Rationale |
|---|---|---|---|
| Standard | 8-12 weeks | 4 weeks | Allows insulin sensitivity to recover; fasting glucose normalizes |
| Low-dose continuous | Continuous at 10 mg | Periodic 2-week breaks every 12 weeks | Low dose (10 mg vs 25 mg) has less metabolic impact; still monitor glucose |
| Metabolically cautious | 8 weeks | 6-8 weeks | For users with borderline glucose markers or family history of T2D |
The insulin sensitivity issue: Murphy et al. (1998) documented that MK-677 at 25 mg/day significantly increased fasting glucose over 8 weeks. The mechanism is straightforward — GH is a counter-regulatory hormone to insulin, and sustained GH elevation (MK-677’s 24-hour half-life means constant stimulation) progressively impairs glucose disposal. A 4-week break is usually sufficient for fasting glucose and insulin sensitivity to return to baseline.
Who can run MK-677 continuously: Users with excellent baseline metabolic health (fasting glucose <90 mg/dL, HbA1c <5.4%, fasting insulin <5 mIU/L) who use 10 mg/day (not 25 mg) and monitor fasting glucose monthly can reasonably run MK-677 for extended periods. Even then, periodic 2-week breaks every 12 weeks are prudent.
Healing Peptides (BPC-157, TB-500)
Healing peptides are fundamentally different from GH peptides because they are intervention-based, not optimization-based. You run them to address a specific problem, and you stop when the problem is resolved.
| Protocol | On-Cycle | Off-Cycle | Rationale |
|---|---|---|---|
| BPC-157 (standard injury) | 4-6 weeks | Stop when healed; restart for new injury | Targeted healing intervention; no evidence of desensitization |
| BPC-157 (severe/chronic injury) | 6-8 weeks | 2-4 weeks, then reassess | Longer cycle for more significant tissue damage |
| TB-500 (standard) | 4-8 weeks | 4 weeks minimum | TB-500’s systemic effects benefit from periodization |
| Wolverine Stack (BPC + TB-500) | 6-8 weeks | 4 weeks | Standard healing stack cycle |
| BPC-157 (gut protocol) | 4-8 weeks | Reassess symptoms; repeat if needed | Gut healing may require 2-3 cycles |
Signs you can stop a healing cycle early:
- Pain has resolved or reduced by 80%+
- Range of motion is fully restored
- The injury passes functional testing (can you do the activities that caused/aggravated it?)
- Gut symptoms have resolved (if running a gut protocol)
Signs you need a longer cycle:
- Pain persists beyond week 4
- Healing has plateaued (was improving but stopped progressing)
- The injury is severe (full tendon tear, post-surgical, chronic condition)
GLP-1 Agonists (Semaglutide, Tirzepatide)
GLP-1 receptor agonists are designed as chronic therapy. They do not require cycling.
| Protocol | Duration | Cycling |
|---|---|---|
| Semaglutide (weight management) | Continuous | No cycling — chronic therapy |
| Tirzepatide (weight management) | Continuous | No cycling — chronic therapy |
| Semaglutide (type 2 diabetes) | Continuous | No cycling — disease management |
Why no cycling: GLP-1 receptor agonists do not cause receptor desensitization at therapeutic doses. The metabolic benefits (A1c reduction, weight loss, cardiovascular risk reduction) are maintained with continuous use. Stopping GLP-1 therapy results in weight regain in the majority of patients — the STEP 1 extension trial showed that patients regained approximately two-thirds of lost weight within one year of stopping semaglutide.
The exception — dose optimization: Some clinicians titrate patients to the minimum effective dose over time. This is dose optimization, not cycling — the medication is continuous, but the dose may decrease once target weight or A1c is achieved.
Nootropic Peptides (Selank, Semax)
| Protocol | On-Cycle | Off-Cycle | Rationale |
|---|---|---|---|
| Selank | 4-6 weeks | 2-4 weeks | GABAergic modulation benefits from periodization; prevents adaptation |
| Semax | 4-6 weeks | 2-4 weeks | BDNF elevation and cognitive effects may plateau without breaks |
| Selank + Semax (Nootropic Stack) | 4-6 weeks | 2-4 weeks | Same timing for the combination |
Nootropic cycling rationale: The evidence for nootropic peptide cycling is less rigorous than for GH peptides. The recommendation is based on the general principle that modulators of neurotransmitter systems (GABAergic for Selank, catecholaminergic/BDNF for Semax) produce better long-term results with periodic breaks than with continuous administration. This prevents neuroadaptation — the brain adjusting to the new baseline and reducing the subjective benefit.
Cosmetic / Anti-Aging Peptides (GHK-Cu, Epitalon)
| Protocol | On-Cycle | Off-Cycle | Rationale |
|---|---|---|---|
| GHK-Cu (injectable) | 8-12 weeks | 4-6 weeks | Copper accumulation risk with extended continuous use; collagen synthesis continues after stopping |
| GHK-Cu (topical) | Continuous | None needed | Topical delivers minimal systemic copper; can be used like a skincare product |
| Epitalon | 10-20 days | 4-6 months | Short pulse protocol is standard for telomerase activation; long break between courses |
| Glow Protocol (BPC + GHK-Cu + TB-500) | 8-12 weeks | 4-6 weeks | Combined cycle based on the longest-cycling component (GHK-Cu) |
GHK-Cu cycling and copper: GHK-Cu delivers exogenous copper bound to the peptide. While GHK-Cu copper delivery is modest compared to dietary copper, extended continuous use (6+ months) without breaks warrants copper/ceruloplasmin monitoring. A 4-6 week break allows copper homeostasis to normalize.
Epitalon’s unique protocol: Epitalon (epithalon) is administered in short intensive courses — typically 5-10 mg/day for 10-20 days — followed by 4-6 month breaks. This protocol is based on the work of Professor Vladimir Khavinson, who demonstrated that short telomerase activation pulses have sustained effects on telomere maintenance. Continuous Epitalon use is not standard and is not supported by the available research.
Immune Peptides (Thymosin Alpha-1, LL-37, KPV)
| Protocol | On-Cycle | Off-Cycle | Rationale |
|---|---|---|---|
| Thymosin Alpha-1 | 4-8 weeks | 4 weeks | Immune modulation; periodization prevents immune overstimulation |
| LL-37 | 2-4 weeks | 4 weeks minimum | Antimicrobial peptide; short targeted courses for active infections |
| KPV | 4-6 weeks | 2-4 weeks | Anti-inflammatory tripeptide; cycle based on symptom resolution |
Master Cycling Reference Table
| Peptide | Standard Cycle | Off-Cycle | Desensitization Risk | Metabolic Risk | Can Run Continuous? |
|---|---|---|---|---|---|
| CJC-1295 + Ipamorelin | 8-12 weeks | 4 weeks | Low | Low | With monitoring (clinical) |
| CJC-1295 + GHRP-2 | 8 weeks | 4 weeks | Moderate | Low-moderate | Not recommended |
| CJC-1295 + GHRP-6 | 4-8 weeks | 4-6 weeks | Moderate | Moderate (cortisol) | Not recommended |
| Hexarelin | 2 weeks max | 4-6 weeks | High | Moderate | No |
| MK-677 | 8-12 weeks | 4 weeks | None | Moderate (insulin) | Low-dose only, with monitoring |
| Sermorelin | 8-12 weeks | 4 weeks | Moderate | Low | With monitoring (clinical) |
| BPC-157 | 4-8 weeks | Until needed again | None known | None | Not recommended (no evidence) |
| TB-500 | 4-8 weeks | 4 weeks | None known | None | Not recommended |
| Semaglutide | Continuous | N/A | None | None | Yes (designed for it) |
| Tirzepatide | Continuous | N/A | None | None | Yes (designed for it) |
| Selank | 4-6 weeks | 2-4 weeks | Low | None | Not recommended (neuroadaptation) |
| Semax | 4-6 weeks | 2-4 weeks | Low | None | Not recommended (neuroadaptation) |
| GHK-Cu (injectable) | 8-12 weeks | 4-6 weeks | None | Low (copper) | Topical only |
| Epitalon | 10-20 days | 4-6 months | None | None | No (pulse protocol) |
| Thymosin Alpha-1 | 4-8 weeks | 4 weeks | None known | None | Not recommended |
Signs You Need a Break
Even within the recommended cycle lengths, pay attention to these signals that your body needs time off:
Physical Signs
- Numbness or tingling in hands/feet — GH-related water retention compressing nerves (carpal tunnel-like symptoms). Reduce dose or take a break.
- Progressive water retention — bloating, facial puffiness, ankle swelling that worsens week over week. Particularly relevant for MK-677 and GHRP-6.
- Joint pain — paradoxically, excessive GH/IGF-1 can cause joint discomfort. If joints hurt more on-cycle than off, your IGF-1 is likely too high.
- Worsening fasting glucose — if home glucose monitoring shows a trend above 100 mg/dL, take a break and reassess.
Efficacy Signs
- Diminishing results — if the same dose produces noticeably less effect than when you started, desensitization is occurring
- Requiring higher doses — if you find yourself increasing dose to maintain the same effect, that is a clear desensitization signal
- Plateau in healing — for BPC-157/TB-500, if healing progress has completely stalled after 4+ weeks, the peptide may have done what it can do
Bloodwork Between Cycles
Use the off-cycle period to get bloodwork. This serves two purposes: confirming that markers have normalized, and establishing a new baseline for the next cycle.
| When | What to Test | Why |
|---|---|---|
| Week 2 of off-cycle | Fasting glucose, fasting insulin | Confirm metabolic markers are normalizing |
| Week 3-4 of off-cycle | IGF-1, fasting glucose, HbA1c, CBC, CMP | Full panel to confirm return to baseline before restarting |
| Before restarting | Same as above (if not recently done) | Fresh baseline for the new cycle |
Common Cycling Mistakes
Mistake 1: Cycling Peptides That Don’t Need It
Running semaglutide or tirzepatide in 8-week cycles with breaks is counterproductive. These are chronic medications. Stopping and restarting causes weight fluctuation, loss of metabolic adaptation, and the need to re-titrate doses. If you are using a GLP-1 agonist, plan for continuous use.
Mistake 2: Not Cycling Peptides That Do Need It
Running GHRP-6 for 16+ weeks continuously leads to progressively elevated cortisol, reduced GH response, and diminishing returns. The “it’s still working, so I’ll keep going” approach ignores metabolic accumulation that isn’t immediately visible but shows up in bloodwork.
Mistake 3: Off-Cycles That Are Too Short
A 1-week break between 12-week cycles is insufficient for receptor recovery or metabolic normalization. Minimum off-cycle duration is 4 weeks for most GH peptides. Rushing back because “I felt worse off-cycle” usually means the off-cycle wasn’t long enough for the body to re-establish homeostasis.
Mistake 4: Stacking Too Many Compounds and Cycling Them All at Once
Starting and stopping 4-5 peptides simultaneously makes it impossible to determine which compound caused which effect (good or bad). If you run a complex stack, consider staggering the start and end dates by 1-2 weeks so you can isolate individual peptide contributions.
Mistake 5: Applying Steroid Cycling Logic to Peptides
Peptides do not suppress the hypothalamic-pituitary-gonadal axis. They do not require post-cycle therapy (PCT). They do not cause the hormonal crash that occurs when stopping testosterone or anabolic steroids. Concepts like “bridge protocols,” “PCT with Clomid/Nolvadex,” and “time on = time off” are steroid paradigms that do not apply to peptides. Cycle based on receptor desensitization and metabolic safety, not steroid folklore.
Related Resources
- Beginner’s First Cycle — how to run your first BPC-157 cycle
- Peptide Safety Guide — storage, injection technique, contraindications
- GH Peptides Compared — all six GH peptides head-to-head
- CJC-1295 Protocol — dosing and cycle-specific details
- MK-677 Protocol — insulin management for long-term use
- BPC-157 Protocol — healing peptide cycle guide
- Reconstitution Calculator — dosing math for your cycle
Frequently Asked Questions
How long should a peptide cycle be? +
It depends on the peptide category. GH secretagogues (CJC-1295, Ipamorelin) are typically cycled 8-12 weeks on, 4 weeks off. Healing peptides (BPC-157, TB-500) run 4-8 weeks based on injury resolution. GLP-1 agonists (semaglutide, tirzepatide) are chronic therapy with no cycling. Nootropic peptides (Selank, Semax) are cycled 4-6 weeks on, 2-4 weeks off. The key variable is receptor desensitization — compounds that desensitize faster require shorter cycles.
Does MK-677 need to be cycled? +
Unlike most GH secretagogues, MK-677 does not cause pituitary desensitization — even after 2 years of continuous use (Nass et al., 2008). However, cycling is still recommended for metabolic reasons. MK-677 progressively worsens insulin sensitivity, and a 4-week break every 8-12 weeks allows glucose metabolism to normalize. Monitor fasting glucose monthly regardless of cycling approach.
What happens if I don't cycle peptides? +
The consequences vary by peptide. GHRPs (especially GHRP-6 and Hexarelin) will lose effectiveness as receptors desensitize — you get progressively less GH per injection. MK-677 won't desensitize but will progressively worsen insulin sensitivity. Healing peptides like BPC-157 do not appear to desensitize but there is no evidence supporting indefinite continuous use. GLP-1 agonists are designed for chronic use and do not need cycling.
Can I run BPC-157 indefinitely? +
There is no published evidence of BPC-157 receptor desensitization. However, BPC-157 is designed as a healing intervention — not a maintenance compound. Standard practice is to run BPC-157 for 4-8 weeks to address a specific healing goal, then stop. If a new injury occurs or healing is incomplete, a new cycle can be started after a 2-4 week break. Running BPC-157 continuously 'just in case' is not supported by evidence and is an unnecessary expense.
Should I do PCT (post-cycle therapy) after a peptide cycle? +
No. PCT (post-cycle therapy) is a concept from anabolic steroid use, where exogenous hormones suppress the body's natural production and recovery assistance is needed. GH secretagogues stimulate natural GH production — they do not suppress it. When you stop a GH peptide, your pituitary returns to its baseline output within days. No PCT is needed for any peptide discussed on this site.